Stay updated on Phase II Pembrolizumab Plus GVD Clinical Trial
Sign up to get notified when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.

Latest updates to the Phase II Pembrolizumab Plus GVD Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA consolidated Locations section lists Florida, New Jersey, and New York sites, replacing the previous separate location subsections. The revision tag updates to v3.3.3 and the old state location sections are removed.SummaryDifference0.3%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedEligibility criteria now require lab values from before Cycle 1 of Pembrolizumab-GVD. Renal function is assessed by eGFR (≥60 mL/min), replacing prior CrCl/GFR language.SummaryDifference0.3%

- Check41 days agoChange DetectedRevision: v3.3.2 added and v3.2.0 removed. This update does not affect study details or eligibility criteria.SummaryDifference0.0%

- Check48 days agoChange DetectedRemoved the government funding status notice/banner from the page. The study details, including interventions, criteria, and contacts, remain unchanged.SummaryDifference0.3%

- Check63 days agoChange DetectedThe page shows minor visual/layout updates and an updated last-updated timestamp. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check91 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference2%

Stay in the know with updates to Phase II Pembrolizumab Plus GVD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.